已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE

克里唑蒂尼 医学 间变性淋巴瘤激酶 内科学 碱性抑制剂 实体瘤疗效评价标准 肿瘤科 临床终点 置信区间 外科 临床研究阶段 胃肠病学 随机对照试验 临床试验 肺癌 恶性胸腔积液
作者
Patrick Schöffski,Michaela Kubickova,Agnieszka Woźniak,Jean‐Yves Blay,Sandra J. Strauss,Silvia Stacchiotti,Tomasz Świtaj,Veit Bücklein,Michael Leahy,Antoîne Italiano,Nicolás Isambert,Maria Dębiec‐Rychter,Raf Sciot,Che-Jui Lee,Frank M. Speetjens,Axelle Nzokirantevye,Anouk Neven,Bernd Kasper
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:156: 12-23 被引量:26
标识
DOI:10.1016/j.ejca.2021.07.016
摘要

PurposeEuropean Organisation for Research and Treatment of Cancer (EORTC) 90101 (CREATE) was a prospective, multicentric, non-randomised, open-label phase II basket trial to assess the efficacy and safety of crizotinib in patients with different types of cancers, including advanced inflammatory myofibroblastic tumour (IMT) with or without anaplastic lymphoma kinase (ALK) rearrangements. Here, we report updated results with long-term follow-up.Patients/methodsAfter central reference pathology, eligible ALK-positive and ALK-negative patients with advanced/metastatic IMT deemed incurable with surgery, radiotherapy or systemic therapy received oral crizotinib 250 mg twice daily. The ALK status was assessed centrally using immunohistochemistry and fluorescence in situ hybridisation. The primary end-point was the proportion of patients who achieved an objective response (i.e. complete or partial response). If ≥6 ALK-positive patients achieved a confirmed response, the trial would be deemed successful.ResultsAt data cut-off on 28th January 2021, we performed the final analysis of this trial. Of the 20 eligible and treated patients (19 of whom were evaluable for efficacy), with a median follow-up of 50 months, five were still on crizotinib treatment (4/12 ALK-positive and 1/8 ALK-negative patients). The updated objective response rate (ORR) was 66.7% (95% confidence interval [CI] 34.9–90.1%) in ALK-positive patients and 14.3% (95% CI 0.0–57.9%) in ALK-negative patients. In the ALK-positive and ALK-negative patients, the median progression-free survival was 18.0 months (95% CI 4.0–NE) and 14.3 months (95% CI 1.2–31.1), respectively; 3-year overall survival rates were 83.3% (95% CI 48.2–95.6) and 34.3% (95% CI 4.8–68.5). Safety results were consistent with previously reported data.ConclusionThese updated results confirm previous findings that crizotinib is effective, with durable responses, in patients with locally advanced or metastatic ALK-positive IMT. With further follow-up after the original primary analysis, the ORR increased, as patients derived long-term benefit and some responses converted from stable disease to partial responses.Clinical trial numberEORTC 90101, NCT01524926.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
T0Yu发布了新的文献求助10
1秒前
丘比特的应助被博修采纳,获得10
1秒前
深情安青的应助被yang采纳,获得10
3秒前
爆米花的应助被yang采纳,获得10
3秒前
大个的应助被yang采纳,获得10
3秒前
JamesPei的应助被yang采纳,获得10
3秒前
SciGPT的应助被yang采纳,获得10
3秒前
科研通AI2S的应助被yang采纳,获得10
3秒前
情怀的应助被yang采纳,获得10
4秒前
Orange的应助被yang采纳,获得10
4秒前
搜集达人的应助被yang采纳,获得10
4秒前
充电宝的应助被yang采纳,获得10
4秒前
7秒前
7秒前
彭于晏的应助被xxdwyd采纳,获得10
9秒前
我吃吃吃吃吃吃完成签到 ,获得积分10
9秒前
10秒前
10秒前
daomaihu发布了新的文献求助100
11秒前
mycoplasma完成签到 ,获得积分10
11秒前
万万发布了新的文献求助10
12秒前
jmc发布了新的文献求助10
12秒前
林深完成签到 ,获得积分10
14秒前
yuanyu发布了新的文献求助10
14秒前
雪山大地发布了新的文献求助10
15秒前
陈预立发布了新的文献求助10
16秒前
思源的应助被鳗鱼雪莲采纳,获得10
17秒前
杏仁和巧克力完成签到 ,获得积分10
17秒前
20秒前
20秒前
SciGPT的应助被温某人采纳,获得10
20秒前
由道罡完成签到 ,获得积分10
21秒前
23秒前
乐乐的应助被橙橙采纳,获得10
24秒前
RRGrel完成签到,获得积分10
25秒前
数据线完成签到 ,获得积分10
26秒前
LIXIA完成签到 ,获得积分10
26秒前
26秒前
认真青曼完成签到,获得积分20
27秒前
夏色弥深完成签到 ,获得积分10
27秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172605
求助须知:如何正确求助?哪些是违规求助? 9565323
关于积分的说明 21778953
捐赠科研通 7764352
什么是DOI,文献DOI怎么找? 3431411
关于科研通互助平台的介绍 2555301
邀请新用户注册赠送积分活动 2476394